Qiagen beats fourth quarter growth consensus after streamlining operations
Share:
(Reuters) - Genetic testing specialist Qiagen beat analysts' expectations for quarterly sales and profit growth on Tuesday, citing savings generated after its decision to stop developing new next-generation sequence (NGS) instruments."We have reallocated resources to support business expansion, while also enabling us to set an outlook for adjusted earnings per share to grow at a significantly faster rate than sales growth," Chief Financial Officer Roland Sackers said.In a surprise to investors,..